PTC Therapeutics (PTCT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

PTC Therapeutics (PTCT) reported $164.68 million in revenue for the quarter ended December 2025, representing a year-over-year decline of 22.8%. EPS of -$1.67 for the same period compares to -$0.24 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $304.72 million, representing a surprise of -45.96%. The company delivered an EPS surprise of -700.58%, with the consensus EPS estimate being -$0.21.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how PTC Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Net product revenue: $183.99 million versus the four-analyst average estimate of $174.53 million. The reported number represents a year-over-year change of +18.9%.
• Revenues- Royalty revenue: $79.39 million compared to the $70.77 million average estimate based on four analysts. The reported number represents a change of +36.5% year over year.
• Revenues- Net product revenue- Translarna: $39 million compared to the $40.42 million average estimate based on three analysts. The reported number represents a change of -58.4% year over year.
• Revenues- Net product revenue- Emflaza: $27.1 million versus $29.58 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -46.3% change.
• Revenues- Collaboration and license revenue: $-0.07 million versus $118.82 million estimated by two analysts on average.

View all Key Company Metrics for PTC Therapeutics here>>>

Shares of PTC Therapeutics have returned -8.8% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

PTC Therapeutics, Inc. (PTCT): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research